Алгоритмы антитромбоцитарной терапии у женщин
Аннотация
В обзоре обоснована разработка алгоритмов антитромбоцитарной терапии (АТТ) у женщин. Подробно рассмотрены специфические гендерные особенности гемостаза и патогенеза тромбозов. Выделены “женские” факторы риска развития тромботических осложнений: прием оральных контрацептивов, беременность и послеродовый период, менопауза и заместительная гормональная терапия. Подробно проанализировано значение АТТ в первичной и вторичной профилактике сердечно-сосудистых заболеваний у женщин. Выделены “особые” показания для назначения ацетилсалициловой кислоты: преэклампсия, антифосфолипидный синдром, мигрень.
Об авторах
О. Н. Ткачева
ФГУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И.Кулакова
Россия
Россия
руководитель терапевтического отделения
Москва, Тел.: +79852118523
Т. В. Кирсанова
ФГУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И.Кулакова
Россия
Россия
терапевт, нефролог отделения
Москва
Н. В. Латышева
ФГУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И.Кулакова
Россия
Россия
научный сотрудник отделения
Москва
Список литературы
1. Stramba-Badiale M., Priori S.G. Gender-specific prescription for cardiovascular diseases? Eur Heart J 2005; 26 (16): 1571-2.
2. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of lowdose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13): 1293-304.
3. Mosca L, Grundy SM, Judelson D, et al. AHA/ACC scientific statement: consensus panel statement. Guide to preventive cardiology for women. American Heart Association/American College of Cardiology. JACC 1999; 33(6): 1751-5.
4. Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595-9.
5. World Health Organization Collaborative Study on Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.
6. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-75.
7. Kurth T, Slomke M, Kase C, et al. Migraine, headache, and the risk of stroke in women. Neurology 2005; 64: 1020-6.
8. Furie KL, Kasner SE, Adams RJ, et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2010 Oct 21. [Epub ahead of print].
9. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109(5): 672-93.
10. Ho PC, Triggs EJ, Heazlewood V, et al. Determination drugs in Plazma by High Performance Liquid Chromatography Br J Clin Pharmacol 1985;19:675-84.
11. Liu Y, Ding J, Bush T. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiol 2001; 154: 489-94.
12. Bailey AL, Scantlebury DC, Smyth SS. Thrombosis and Antithrombotic Therapy in Women Arteriosclerosis. Thromb Vasc Biol 2009; 29: 284.
13. Kaptoge S, White IR, Thompson SG, et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007; 166: 867-79.
14. Bushnell CD, Hurn P, Colton C, et al. Advancing the study of stroke in women: Summary and recommendations for future research from an NINDS-sponsored multidisciplinary working group. Stroke 2006; 37: 2387-99.
15. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11.
16. Peters LL, Cheever EM, Ellis HR, et al. Large-scale, highthroughput screening for coagulation and hematologic phenotypes in mice. Physiol Genomics 2002; 11: 185-93.
17. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 1997; 77: 748-54.
18. Haque SF, Matsubayashi H, Izumi S, et al. Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J 2001; 48: 33-41.
19. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975; 253: 355-7.
20. Uzunova A, Ramey E, Ramwell PW. Effect of testosterone, sex and age on experimentally induced arterial thrombosis. Nature 1976; 261: 712-3.
21. Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 1977; 232: H381-5.
22. Leng XH, Hong SY, Larrucea S, et al. Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler Thromb Vasc Biol 2004; 24: 376-81.
23. Leng XH, Zhang W, Nieswandt B, Bray PF. Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res 2005; 97: 415-7.
24. Jordan WM. Pulmonary embolism. Lancet 1961; 2: 1146-7.
25. Poller L, Priest C, Thomson J. Platelet aggregation during oral contraception. Br Med J 1969; 4: 273-4.
26. Helmrich SP, Rosenberg L, Kaufman DW, et al. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987; 69: 91-5.
27. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolis disorders: an international case-control study. BMJ 1996; 312: 83-7.
28. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305: 612-8.
29. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986; 292: 526.
30. Bottiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effect of lowering estrogen content. Lancet 1980; 1: 1097-101.
31. Саидова Р.А., Макацария А.Д., Джангидзе М.А. Гормональные контрацептивы — оптимальный выбор. РМЖ 1999; 7(18): 878-82.
32. Comp PC. Thromboembolic mechanisms of OCs. In: Benefits and riscs of Ocs: A Current Perspective. Symposium Monograph. New Jersey 1997; 5-9.
33. Пузырькова И.А. Гемостазиологический скрининг при гормональной контрацепции. Акуш и гин 1999; 2: 34-7.
34. Newton JR. Classification and comparison of oral contraceptives containing new generation progestagens. Human Reproduction Update 1995; 1: 231-63.
35. Speroff L, Decherney A. Evaluation of a new generation of oral contraceptives. The advisory Board for the New Progestins. Obstet Gynecol 1993; 81: 1034-47.
36. Olivieri O, Friso S, Manzato F, et al. Resistance to Activated Protein C, Associated with Oral Contraceptives Use; Effect of Formulations, Duration of Assumption, and Doses of OestroProgestins. Contraception 1996; 54: 149-52.
37. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
38. Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein С in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
39. Серов В.Н., Макацария А.Д. Тромботические и геморрагические осложнения в акушерстве. Москва 1987; 288 с.
40. Boda Z, Laszlo P, Pfliegler G, et al. Thrombophilia, anticoagulant therapy and pregnancy. Orvosi Hetilap 1998; 139: 3113-6.
41. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
42. Rey E, Kahn RS, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-8.
43. Branch DW, Andres R, Digre KB, et al. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989; 73: 541-5.
44. Dreyfus M, Hedelin G, Kutnahorsky R, et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstet Gynecol 2001; 97: 29-34.
45. Dekker GA, de Vries JIP, Doelitzsch PM, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-8.
46. Dizon-Townson D, Miller C, Sibai B, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106: 517-24.
47. Mello G, Parretti E, Marozio L, et al. Thrombophilia is significantly associated with severe preeclampsia. Results of a large scale, care-controlled study. Hypertension 2005; 46: 1270-4.
48. Gris JC, Mercier E, Quere I, et al. Lowmolecular- weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-9.
49. Robertson L, Wu O, Langhorne P, et al. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-28.
50. Макацария А.Д. Гемостазиологические аспекты акушерских кровотечений. Акуш и гинек 1985; 1: 22-8.
51. Баркаган З.С. Клинико-патогенетические варианты, номенклатура и основы диагностики гематогенных тромбофилий. Пробл гематол 1996; 3: 5-15.
52. Brenner B. Inherited thrombophilia and pregnancy loss. J Thromb Haemost 1999; 82 (2): 634-41.
53. Gris JC, Ripart-Neveu S, Maugard С, et al. Thromb. Respective evaluation of the prevalence of haemostasis abnormatilies in unexplaind primary early recurrent miscarriages. The Nimes obstetricians and Haematologists (NOHA) Study He-most 1997; 77: 1096-103.
54. Гаспарян С.А., Модина М.А., Чотчаева С.М., Лифенко Р.А. Динамика показателей тромбоцитарного звена гемостаза при физиологическом и осложненном течении беременности. Матер Второго Межд Конгресса по репродуктивной медицине Репродуктивное здоровье семьи. Проблемы репродукции. Спец. Выпуск 2008; 62-4.
55. Rutherford S, Montoro M, McGhee W, Strong T. Thromboembolic disease associated with pregnancy: an 11 year review (abstract). Am J Obstet Gynecol 1991; 164(Suppl): 286.
56. Matthews KA, Meilahn E, Kuller LH, et al. N EnglJ Med 1989; 321: 641-6.
57. Wilson W, Stampfer MJ, Bain C, et al. Cigarette smoking, relativeweight and menopause 1983; 117: 651-8.
58. Wing R.J.R., Mattews K.A., Kuller Ш., Weight gain at the time of menopause, Arch Inter Med 1991; 151: 97-102.
59. Folsom AR, Wu KK, Davis CE. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factor II. Atherosclerosis 1991; 91: 191-205.
60. Brunner EJ, Marmot MG, White IR, et al. Gender and employment grade differences in blood cholesterol, apolipoproteins and haemostatic factors in the Whitehall II study. Atherosclerosis 1993; 102(2): 195-207.
61. Gebara OSE, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potencial in the Framingham Offspring Study. Circulation 1995; 91: 1952-8.
62. Banks E, Canfell K. Invited Commentary: Hormone Therapy Risks and Benefits-The Women’s Health Initiative Findings and the Postmenopausal Estrogen Timing Hypothesis. Am J Epidemiol 2009; 170: 24-8.
63. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979; 242: 1150-4.
64. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogenreplacement therapy II: a prospective study in the relationship to carcinomaand cardiovascular and metabolic problems. Obstet Gynecol 1979; 54(1): 74-9.
65. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642-5.
66. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
67. Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3.
68. Lim SC, Caballero A.E, Arora S, et al. The Effect of Hormonal Replacement Therapy on the Vascular Reactivity and Endothelial Function of Healthy Individuals and Individuals with Type 2 Diabetes. J Clin Endocrinol Metab 1999; 84: 4159-64.
69. Scarabin PY, Alhenc-Celas M, Plu-Bureau G, et al. Effects of oral and mnsdermi estrogen/progesterone regimens on blood coagulation and fibrinolysis In postmen-pausal women. Arterioscler Thromb Vase Biol 1997; 17: 3071-8.
70. Scarabin PY, Oger E, Plu Bureau G. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-32.
71. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric 2004; 7: 347-56.
72. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
73. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. JACC 2003; 41: 961-5.
74. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006; 295: 1420-7.
75. The Steering Committee for the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989; 321(3): 129-35.
76. Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-6.
77. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998; 351(9098): 233-41.
78. Hannson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.
79. Collaborative Group of the Primary Prevention Project. Lowdose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357: 89-95.
80. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-3.
81. Mosca L. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. JACC 2007; 49(11): 1230-50.
82. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
83. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349.
84. Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev 2000; (2): CD000492.
85. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343: 619-29.
86. Askie LM, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. The Lancet, 369(9575): 1791-8.
87. Balasch J, Cervera R. Reflections on the management of reproductive failure in the antiphospholipid syndrome — the clinician’s perspective. Lupus 2002; 11: 467-77.
88. Derksen R, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50: 1028-31.
89. Richter C, Sitzmann J, Lang P, et al. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol 2001; 52(6): 708-10.
90. Carmona F, Font J, Azulay M, et al. Risk factor associated with fetal losses in treatd antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001; 46: 274-9.
91. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheumatism 2003; 48: 728-34.
92. Ruffati A, Favaro M, Tonello M, et al. Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospectiva cohort study. Lupus 2004; 14: 120-8.
93. Насонов Е.Л. Антифосфолипидный синдром: клиническая и иммунологическая характеристика. Клин мед 1989; 1:5-13.
94. McCrae KR. Antiphospholipid antibody associated thrombosis: a consensus for treatment? Special article. Lupus 1996.
95. Meroni PL, Moia M, Derksen RHWM et al. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus 2003; 12: 504-7.
96. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and metaanalysis of observational studies. BMJ 2005; 330: 63-5.
97. MacClellan LR, Giles WH, Cole J, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 2007; 38: 2438-45.
98. Kurth T, Gaziano JM, Cook NR, et al. Migraine and risk of cardiovascular disease in women. JAMA 2006; 296: 283-91.
99. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health OrganisationCollaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999; 318: 13-8.
Рецензия
Для цитирования:
Ткачева О.Н., Кирсанова Т.В., Латышева Н.В. Алгоритмы антитромбоцитарной терапии у женщин. Кардиоваскулярная терапия и профилактика. 2011;10(1):110-119.
For citation:
Tkacheva O.N., Kirsanova T.V., Latysheva N.V. Anti-platelet therapy algorithms in women. Cardiovascular Therapy and Prevention. 2011;10(1):110-119. (In Russ.)
Просмотров:
434
Послать статью по эл. почте 
